Profund Advisors
ORIC icon

Profund Advisors’s Oric Pharmaceuticals ORIC Stock Holding History

Profund Advisors’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$499K Sell
37,027
-8,673
-19% -$108K 0.01% 571
2026
Q2 		$495K Sell
45,700
-5,819
-11% -$52.8K 0.01% 560
2026
Q1 		$653K Sell
51,519
-13,641
-21% -$155K 0.02% 466
2025
Q4 		$533K Buy
65,160
+46,440
+248% +$535K 0.02% 540
2025
Q3 		$225K Buy
+18,720
New +$197K 0.01% 909
2025
Q2 		– Sell
-16,469
Closed -$91.9K – 1033
2025
Q1 		$91.9K Buy
16,469
+5,651
+52% +$49.4K ﹤0.01% 958
2024
Q4 		$87.3K Sell
10,818
-2,684
-20% -$24.6K ﹤0.01% 1078
2024
Q3 		$138K Sell
13,502
-8,359
-38% -$82.6K 0.01% 1090
2024
Q2 		$155K Buy
21,861
+4,175
+24% +$37.4K 0.01% 1017
2024
Q1 		$243K Buy
+17,686
New +$210K 0.01% 970

Other funds holding ORIC

Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Profund Advisors's ORIC Position: Q3 2026 in Review

Profund Advisors reduced its Oric Pharmaceuticals (ORIC) stake by 19% in Q3 2026, selling an estimated $108K and leaving 37,027 shares worth $499K. The position accounts for 0.01% of the portfolio, ranked #571.

Profund Advisors first reported a position in ORIC in Q1 2024 and has held it in 10 quarters since. The position peaked at $653K in Q1 2026. 27 funds tracked by Wall St. Rank hold ORIC as of Q3 2026.

  • Profund Advisors held 37,027 shares of Oric Pharmaceuticals worth $499K as of Q3 2026.
  • Profund Advisors sold 8,673 Oric Pharmaceuticals shares in Q3 2026, an estimated $108K.
  • Oric Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q3 2026, its #571 holding.
  • Profund Advisors first reported a position in Oric Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Profund Advisors's Oric Pharmaceuticals position peaked at $653K in Q1 2026.
  • 27 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.